CoChat

RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models

Open access
Garner, Fiona, Shomali, Maysoun, Paquin, Dotty, Lyttle, C. Richard, Hattersley, Gary · 2015 · Anti-Cancer Drugs
Cited by 157

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Agents that inhibit estrogen production, such as aromatase inhibitors or those that directly block estrogen receptor (ER) activity, such as selective estrogen receptor modulators and selective estrogen receptor degraders, are routinely used in the treatment of ER-positive breast cancers. However, although initial treatment with these agents is often successful, many women eventually relapse with drug-resistant breast cancers. To overcome some of the challenges associated with current endocrine therapies and to combat the development of resistance, there is a need for more durable and more effective ER-targeted therapies. Here we describe and characterize a novel, orally bioavailable small-molecule selective estrogen receptor degrader, RAD1901, and evaluate its therapeutic potential for the treatment of breast cancer. RAD1901 selectively binds to and degrades the ER and is a potent antagonist of ER-positive breast cancer cell proliferation. Importantly, RAD1901 produced a robust and profound inhibition of tumor growth in MCF-7 xenograft models. In an intracranial MCF-7 model, RAD1901-treated animals survived longer than those treated with either control or fulvestrant, suggesting the potential benefit of RAD1901 in the treatment of ER-positive breast cancer that has metastasized to the brain. Finally, RAD1901 preserved ovariectomy-induced bone loss and prevented the uterotropic effects of E2, suggesting that it may act selectively as an agonist in bone but as an antagonist in breast and uterine tissues. RAD1901 is currently under clinical study in postmenopausal women with ER-positive advanced breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/cad.0000000000000271

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 18

  1. Yager, 2006, Estrogen carcinogenesis in breast cancer., N Engl J Med, 354, 270, 10.1056/NEJMra050776 · DOI · Paper page
  2. Stein, 2006, Estrogen-related receptor alpha as a therapeutic target in cancer., Endocr Relat Cancer, 13, S25, 10.1677/erc.1.01292 · DOI · Paper page
  3. Yue, 2013, Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis., Steroids, 78, 161, 10.1016/j.steroids.2012.11.001 · DOI · Paper page
  4. Stingl, 2011, Estrogen and progesterone in normal mammary gland development and in cancer., Horm Cancer, 2, 85, 10.1007/s12672-010-0055-1 · DOI
  5. Pinkerton, 2014, Use of SERMs for treatment in postmenopausal women., J Steroid Biochem Mol Biol, 142, 142, 10.1016/j.jsbmb.2013.12.011 · DOI
  6. Swaby, 2007, SERMs for the treatment and prevention of breast cancer., Rev Endocr Metab Disord, 8, 229, 10.1007/s11154-007-9034-4 · DOI
  7. Jordan, 2007, Chemoprevention of breast cancer with selective oestrogen-receptor modulators., Nat Rev Cancer, 7, 46, 10.1038/nrc2048 · DOI · Paper page
  8. Di Leo, 2010, . Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer., J Clin Oncol, 28, 4594, 10.1200/JCO.2010.28.8415 · DOI · Paper page
  9. Van Kruchten, 2015, . Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer., Cancer Discov, 5, 72, 10.1158/2159-8290.CD-14-0697 · DOI · Paper page
  10. Evans, 1988, The steroid and thyroid hormone receptor superfamily., Science, 240, 889, 10.1126/science.3283939 · DOI · Paper page
  11. Singh, 2005, Steroid hormone receptor signaling in tumorigenesis., J Cell Biochem, 96, 490, 10.1002/jcb.20566 · DOI
  12. McDonnell, 2002, Connections and regulation of the human estrogen receptor., Science, 296, 1642, 10.1126/science.1071884 · DOI · Paper page
  13. Burns, 2012, Estrogen receptors and human disease: an update., Arch Toxicol, 86, 1491, 10.1007/s00204-012-0868-5 · DOI · Paper page
  14. Herynk, 2007, Estrogen receptors in resistance to hormone therapy., Adv Exp Med Biol, 608, 130, 10.1007/978-0-387-74039-3_10 · DOI
  15. Kalu, 1991, The ovariectomized rat model of postmenopausal bone loss., Bone Miner, 15, 175, 10.1016/0169-6009(91)90124-I · DOI · Paper page
  16. Lai, 2015, . Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts., J Med Chem, 58, 4888, 10.1021/acs.jmedchem.5b00054 · DOI · Paper page
  17. Wardell, 2011, The turnover of estrogen receptor by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy., Biochem Pharmacol, 82, 122, 10.1016/j.bcp.2011.03.031 · DOI · Paper page
  18. Maximov, 2013, The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice., Curr Clin Pharmacol, 8, 135, 10.2174/1574884711308020006 · DOI · Paper page

Cited by

See all 157

Metadata

Authors
Garner, F., Shomali, M., Paquin, D., Lyttle, C. R., & Hattersley, G.
Venue
Anti-Cancer Drugs
Published
2015-10
Volume
26
Issue
9
Pages
948-956
ISSN
0959-4973 (ISSN-L)
OpenAlex
W2395038895
Cited by
157
References
1
FWCI
8.02
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. https://app.cochat.ai/papers/10.1097/cad.0000000000000271
The paper
Garner, F., Shomali, M., Paquin, D., Lyttle, C. R., & Hattersley, G. (2015). RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anti-Cancer Drugs. https://doi.org/10.1097/cad.0000000000000271

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.